Centiva Capital’s TG Therapeutics TGTX Stock Holding History

Centiva Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-25,654	Closed	-$500K	–	874
2020 Q2	$500K	Buy	+25,654	New	+$413K	0.03%	290

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Centiva Capital's TGTX Position: Q3 2020 in Review

Centiva Capital sold out of TG Therapeutics (TGTX) in Q3 2020, closing a stake of 25,654 shares — an estimated $500K sold.

Centiva Capital first reported a position in TGTX in Q2 2020 and held it in 1 quarter. The position peaked at $500K in Q2 2020. 181 funds tracked by Wall St. Rank hold TGTX as of Q3 2020.

Centiva Capital reported no remaining TG Therapeutics position as of Q3 2020 after selling out during the quarter.
Centiva Capital sold 25,654 TG Therapeutics shares in Q3 2020, an estimated $500K.
Centiva Capital first reported a position in TG Therapeutics in Q2 2020 and held it in 1 quarter.
Centiva Capital's TG Therapeutics position peaked at $500K in Q2 2020.
181 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2020.

Based on Centiva Capital's 13F filing for Q3 2020, filed 16 Nov 2020.